NIKKEI 225
27,333.10 +387.43 (+1.44%) HANG SENG
19,258.76 0.00 (0.00%) CRUDE OIL
69.50 +0.17 (+0.25%) GOLD FUTURES
1,948.20 +7.10 (+0.37%) DOW
32,560.60 +316.02 (+0.98%) BTC-GBP
23,022.06 +243.19 (+1.07%)
Hutchison China MediTech Limited (HCM.L)
| Previous close | 231.50 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 243.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 147,616 |
| Market cap | 2.11B |
| Beta (5Y monthly) | 0.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -13.00 |
| Earnings date | 28 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.40 |
- Globe Newswire
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that, further to its announcement on January 23, 2023 and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive license agreement with a subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502, NYSE:TAK) to further the global development, commercialization and manufac
- Globe Newswire
HUTCHMED Confirms No Assets Held at Silicon Valley Bank
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today confirms that it does not have any exposure to Silicon Valley Bank (“SVB”) or Silicon Valley Bank UK Limited (“SVBUK”). The Company does not hold any cash deposits or securities with SVB or SVBUK. About HUTCHMED HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is comm
- Globe Newswire
HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
Landmark licensing deal with Takeda for fruquintinib outside of China, bringing HUTCHMED up to US$1.13 billion, plus royalties, and demonstrating execution of the new global strategy Record Full Year 2022 oncology/immunology revenues driven by significant increase in China in-market sales of ELUNATE®, SULANDA® and ORPATHYS® alongside clinical and strategic progress Company to Host Annual Results Call & Webcast Today at 9 p.m. HKT / 1 p.m. GMT / 8 a.m. EST HONG KONG, SHANGHAI, China and FLORHAM P
